Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Deuterated phenanthrene ([D10]Phe) is a stable isotope-labeled small molecule used as a non-carcinogenic surrogate biomarker to study the metabolic activation of polycyclic aromatic hydrocarbons (PAHs) in humans. Developed by the Masonic Cancer Center at the University of Minnesota, it serves as a tracer to model the metabolism of environmental carcinogens like benzo[a]pyrene, which are found in tobacco smoke. By measuring urinary metabolites such as [D10]phenanthrene tetraol ([D10]PheT) and [D10]phenanthrols ([D10]HOP), researchers can assess the impact of chemopreventive agents, such as glucobrassicin-rich Brussels sprouts, on PAH detoxification pathways. It is typically administered in microgram doses and is used to distinguish administered phenanthrene from environmental exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on deuterated phenanthrene.